Report Produced: 03/29/2023 06:40 AM
|Report||Question ID||Question||Discussion||Answer (Ascending)|
|20051047||First Course Treatment--Immunotherapy: Is anti-thymocyte globulin coded as immunotherapy?||Do not code anti-thymocyte globulin as cancer treatment. Anti-thymocyte globulin is used to treat transplant rejection.|
|20031173||Hormone Therapy--Thyroid: Is pre-op hormone replacement therapy coded in this field? See Description.||Patient was admitted for thyroidectomy with a diagnosis of probable thyroid cancer. Patient's history stated that patient received work-up for hypothyroidism and was found to have thyroid nodule. FNA suggested carcinoma. Patient's medications included Cytomel and Synthroid.||Do not code hormone replacement given to treat hypothyroidism as cancer treatment. Thyroid hormone therapy is coded as treatment only for follicular and papillary thyroid carcinomas.|
|20051064||Cancer-Directed Treatment/Surgery of Primary Site--Anus: Is "infrared coagulation" coded as surgery or "other" treatment for anal canal primaries?||Do not code infrared coagulation -- it is not treatment for cancer.|
|20051038||First Course Treatment--Prostatic Urethra: Is Lupron coded for a papillary carcinoma of the prostatic urethra that is treated with a TUR with fulguration and beam radiation even though the prostate biopsies are negative?||Do not code lupron as treatment for a primary in the prostatic urethra.|
|20130156||Other therapy--Heme and Lymphoid Neoplasms: Based on the hematopoietic manual instructions, is plasmapheresis coded as treatment for Waldenstrom macroglobulinemia? See Discussion.||
A patient, who was diagnosed with Waldenstrom macroglobulinemia at another facility, presented to our facility for plasmapheresis on 12/27/2012. No other treatment was given.
How is the plasmapheresis coded for treatment?
|Do not code plasmapheresis as treatment. It does not modify the neoplasm.|
|20061050||Neoadjuvant Treatment/Date Therapy Initiated--Breast: If Tamoxifen has been used since 2000 for the treatment of hyperplasia, should it be coded as neoadjuvant treatment for a 2004 diagnosis of breast cancer?||Do not code tamoxifen given for hyperplasia as treatment for breast cancer. In this case, tamoxifen started four years before the breast cancer diagnosis -- not treatment for breast cancer.|
|20071053||Grade, Differentiation: How is grade coded for cases using the FNCLCC (Federation Nationale des Centres de Lutte Contre Ie Cancer) system? See Discussion.||Is FNCLCC a recognized system in the United States? Tongue was the primary site for the case we saw that used FNCLCC.||Do not code the data item Grade based on the FNCLCC grade. You may record the FNCLCC grade in a text field.|
|20110054||First course treatment/Other therapy--Heme & Lymphoid Neoplasms: Is a transfusion coded as first course treatment for multiple myeloma? See Discussion.||Per the SEER Manual, First Course for Leukemia and Hematopoietic Diseases definitions, Other Hematopoietic states that transfusions are coded as "other" in the Other Treatment fields. Does this mean that a transfusion for chemotherapy-related anemia is coded as treatment for patients with multiple myeloma?||Do not code transfusions as treatment. According to hematopoietic specialty physicians, transfusions are given for such a variety of reasons (anemia, etc.) and should not be coded as other treatment.|
Terms of involvement--Lung: Is "intense uptake" described on a PET scan an indication of involvement? See Description.
We are seeing increasing use of PET scans as diagnostic tools for cancer. PET scans use different terminology than the ambiguous terms listed in the EOD manual. Could we please have guidelines for interpreting PET scans?
Example: Patient with right lung cancer. PET scan showed intense uptake in the mediastinum and in the hilum. Can we code "intense uptake" as involvement of mediastinal and hilar lymph nodes?
|Do not interpret "intense uptake" as involvement. Look for a statement of involvement or other terminology, such as "highly suspicious," "strongly suspicious for" malignancy, involvement, etc.|
|20100103||Reportability--Corpus uteri: Is gestational trophoblastic neoplasia reportable if there is no mention of metastasis but the patient has been treated with chemotherapy? See Discussion.||
Per SINQ 20021106, for tumors diagnosed prior to 2007, a clinical diagnosis of metastatic gestational trophoblastic disease was to be coded to histology 9100/3 [Choriocarcinoma]. "Gestational trophoblastic neoplasia includes the diagnosis of choriocarcinoma."
|Do not report gestational trophoblastic neoplasia unless stated to be malignant.|